background
vaccin
adjuv
compound
significantli
enhanceprolong
immun
respons
coadminist
antigen
limit
use
aluminium
salt
unabl
elicit
cell
respons
intracellular
pathogen
caus
malaria
tuberculosi
aid
driven
develop
new
altern
adjuv
triterpen
saponin
purifi
quillaja
saponaria
purpos
aim
review
attempt
clarifi
mechan
action
either
receptor
signal
pathway
vitro
vivo
special
emphasi
coadministr
immunostimul
new
adjuv
formul
call
adjuv
system
furthermor
relev
clinic
applic
present
method
literatur
search
cover
period
perform
use
electron
databas
sci
finder
scienc
direct
medlinepubm
scopu
googl
scholar
result
insight
mechan
action
summar
follow
vivo
stimul
humor
cellmedi
immun
respons
action
antigen
present
cell
apc
cell
lead
releas
cytokin
particip
elimin
intracellular
pathogen
activ
inflammasom
mous
apc
subsequ
releas
depend
cytokin
import
respons
synthesi
nearli
analog
allow
structureact
relationship
mechanist
studi
uniqu
synergi
mechan
monophosphoryl
lipid
mpl
formul
liposom
earli
respons
promot
vaccin
immunogen
second
part
review
relat
phase
iiii
clinic
trial
mostli
formul
ass
evalu
efficaci
immunogen
safeti
adjuv
prophylact
vaccin
infecti
diseas
eg
malaria
herp
zoster
tuberculosi
aid
therapeut
vaccin
cancer
alzheim
diseas
conclus
advanc
phase
iii
clinic
applic
led
develop
two
vaccin
contain
part
herp
zoster
vaccin
hzsu
receiv
licens
fda
market
author
eu
rt
vaccin
malaria
approv
ema
implement
subsaharan
countri
routin
use
made
research
vaccin
attract
last
decad
lee
nguyen
modern
subunit
vaccin
compris
homogen
molecular
antigen
develop
prevent
treat
mani
human
diseas
weakli
immunogen
must
administ
adjuv
elicit
potent
immun
respons
adjuv
whose
name
origin
latin
word
adjuvar
http
doi
vaccin
effect
least
expens
methodolog
prevent
diseas
caus
infecti
pathogen
recent
emerg
reemerg
diseas
sever
acut
respiratori
syndrom
sar
influenza
pandem
ebola
viru
mean
help
substanc
use
combin
specif
antigen
ag
produc
potent
persist
immun
respons
specif
diseas
ag
alon
aim
confer
longterm
protect
addit
benefit
less
antigen
fewer
inject
need
lee
nguyen
adjuv
use
mani
vaccin
mechan
action
fulli
elucid
includ
divers
class
compound
miner
salt
microbi
product
emuls
saponin
cytokin
polym
microparticul
liposom
awat
et
al
adjuv
approv
use
human
del
giudic
et
al
aluminium
salt
extens
use
adjuv
vaccin
year
induc
robust
antibodi
respons
weak
cell
type
respons
instrument
protect
mani
pathogen
new
gener
vaccin
use
purer
compon
safer
vaccin
eg
subunit
vaccin
highli
purifi
recombin
antigen
less
immunogen
contrast
live
attenu
inactiv
wholecel
vaccin
therefor
requir
induct
strong
cellular
respons
includ
thelper
cell
th
cytotox
lymphocyt
ctl
addit
antibodi
ab
respons
thu
develop
new
adjuv
necessari
vaccin
requir
cellmedi
immun
respons
cmi
among
triterpen
glycosid
repres
interest
class
clinic
relev
adjuv
particularli
quillaja
saponaria
qs
amphiphat
plant
glycosid
possess
varieti
pharmacolog
activ
includ
immunoadjuv
antitumor
antiinflammatori
antimicrobi
properti
extens
studi
mani
vitro
vivo
bioassay
lacailleduboi
wagner
lacailleduboi
despit
appar
success
vaccineadjuv
last
year
urgent
need
deeper
understand
mode
action
could
acceler
develop
new
vaccin
strategi
requir
interdisciplinari
approach
chemist
biochemist
molecular
biologist
immunologist
follow
review
summar
updat
insight
mode
action
structureact
relationship
allow
detail
mechanist
studi
clinic
statu
vaccin
adjuv
grow
understand
innat
immun
system
respons
first
mediat
antigen
present
cell
apc
role
activ
modul
adapt
immun
respons
agspecif
b
cell
respons
di
pasqual
et
al
mechan
action
adjuv
elucid
act
one
follow
target
increas
respons
ag
sustain
releas
inject
site
depot
effect
transient
secret
cytokin
chemokin
recruit
variou
immun
cell
neutrophil
monocyt
eosinophil
macrophag
dendrit
cell
dc
inject
site
lead
local
immunecompet
environ
express
recruit
apc
variou
pathogen
recognit
receptor
prr
surfac
tolllik
receptor
tlr
ctype
lectin
receptor
clr
intracellularli
nucleotid
oligomer
domain
nod
like
receptor
nlr
retino
induc
rig
like
receptor
rlr
recogn
andor
activ
adjuv
matur
activ
recruit
apc
upregul
express
major
histocompat
complex
mhc
andor
mhcii
activ
costimulatori
signal
increas
capac
apc
ag
process
present
mhc
migrat
matur
apc
drain
lymph
node
dln
interact
agspecif
b
lymphocyt
receptorligand
interact
mhct
cell
receptor
mhctcr
activ
produc
potent
absecret
b
cell
andor
effector
cell
respons
awat
et
al
research
continu
character
adapt
immun
respons
clarifi
respect
role
vaccineinduc
immun
effector
fig
includ
ab
produc
b
lymphocyt
bind
specif
toxin
pathogen
memori
b
cell
produc
b
cell
receiv
cell
help
abil
respond
rapid
reexposur
antigen
cytotox
lymphocyt
limit
spread
infecti
agent
kill
infect
cell
secret
specif
cytokin
helper
th
lymphocyt
variou
th
subset
defin
cytokin
profil
abil
induc
b
cell
cell
respons
reed
et
al
siegrist
cell
essenti
releas
awat
et
al
reed
et
al
lacailleduboi
wagner
phytomedicin
proinflammatori
cytokin
tumor
necrosi
particip
elimin
intracellular
pathogen
directli
cytokin
respons
indirectli
via
cell
activ
differenti
ctl
cellular
immun
respons
gener
mice
complementfix
ab
cell
respons
character
secret
provid
b
cell
help
preferenti
induct
ige
iga
mice
ige
human
humor
respons
guy
saponin
isol
quillaja
saponaria
tree
bark
kensil
et
al
one
potent
adjuv
known
current
use
exploratori
licens
vaccin
mixtur
two
isomer
molecul
apios
api
xylos
four
domain
triterpen
quillaic
acid
branch
trisaccharid
link
oheterosid
bound
linear
tetrasaccharid
link
ester
bound
glycosyl
pseudodimer
acyl
chain
attach
labil
ester
linkag
fucos
unit
tetrasaccharid
fig
compound
show
potent
adjuv
activ
wide
varieti
ag
low
toxic
preclin
studi
mice
guinea
pig
monkey
baboon
shown
stimul
immun
respons
ad
vaccin
kensil
adjuv
candid
mani
clinic
trial
vaccin
direct
infecti
diseas
cancer
other
howev
exact
role
either
activ
receptor
signal
pathway
poorli
character
hypothes
advanc
may
facilit
ag
uptak
apc
bind
cell
surfac
lectin
carbohydr
domain
lead
specif
cytokin
profil
enhanc
andor
b
cell
respons
marciani
effect
mechan
action
appar
act
dc
cell
propos
marciani
fig
exogen
ag
enter
dc
cholesteroldepend
endocytosi
high
affin
endosom
membran
cholesterol
result
destabil
membran
lorent
et
al
lead
pore
format
thu
facilit
escap
antigen
cytosol
process
insid
cell
peptid
load
mhci
present
dc
surfac
cell
yield
ctl
role
aldehyd
highlight
cell
form
imin
amino
group
cell
surfac
receptor
provid
costimulatori
signal
cell
signal
togeth
mitogenactiv
protein
kinas
mapk
result
activ
tcrmhc
interact
chang
ionic
balanc
na
k
stimul
cell
activ
result
secret
cytokin
marciani
fig
recent
studi
mous
apc
dc
macrophag
identifi
activ
inflammasom
combin
lipid
mpl
shown
activ
inflammasom
multiprotein
complex
caus
subsequ
releas
depend
proinflammatori
cytokin
promot
th
cell
matur
drive
respons
respect
martyroix
et
al
thu
inflammasom
signal
potenti
direct
develop
helper
subset
howev
role
signal
pathway
vivo
remain
clarifi
although
use
mani
clinic
investig
vaccin
sever
drawback
inher
natur
product
chemic
instabl
scarciti
heterogen
doselimit
toxic
poorli
understood
mechan
action
limit
widespread
clinic
advanc
except
recent
malaria
shingl
vaccin
develop
glaxosmithklin
gsk
overcom
limit
structur
modif
natur
product
chemic
synthesi
undertaken
last
decad
lead
prepar
nearli
saponin
analog
provid
key
insight
structureact
relationship
sar
summar
fig
achiev
allow
identif
new
novel
saponin
probe
potent
adjuv
activ
increas
stabil
decreas
toxic
investig
mechan
action
et
al
firstli
total
synthesi
isomer
produc
potent
adjuv
high
puriti
homogen
composit
variant
chemic
synthes
stabl
amid
linkag
acyl
chain
instead
unstabl
nativ
ester
fig
immunolog
evalu
mice
demonstr
adjuv
activ
compar
assess
measur
ab
respons
elisa
one
week
booster
inject
day
significantli
lower
toxic
natur
product
except
modif
acyl
chain
dodecanedio
acid
truncat
tetrasaccharid
led
trisaccharid
variant
potent
adjuv
activ
whose
toxic
issu
complet
resolv
simplif
led
structur
variat
linker
ester
linkag
triterpen
linear
oligosaccharid
order
modul
distanc
orient
two
domain
variant
exhibit
strike
differ
adjuv
activ
toxic
mous
vaccin
model
yield
new
insight
structur
requir
adjuv
activ
molecular
dynam
simul
compound
api
reveal
distinct
conform
featur
correl
adjuv
activ
may
help
design
new
analog
walkowicz
et
al
modif
tetrasaccharid
trisaccharid
variant
acyl
chain
termin
amin
variant
enabl
synthesi
novel
acyl
chain
variant
bear
fluoresc
iodin
substitu
subsequ
imag
vivo
biodistribut
studi
et
al
adjuvantact
sever
mousevaccin
model
less
toxic
earli
studi
biodistribut
fluoresc
imag
allow
investig
enigmat
mechan
action
saponin
preliminari
result
vaccin
mice
suggest
potenti
role
fluoresc
probe
ag
ovalbumin
ova
traffick
apc
site
inject
ln
present
immun
system
yield
mechanist
understand
potenti
immun
respons
et
al
extens
structurefunct
studi
shown
aryl
iodid
deriv
free
oh
display
good
efficaci
toxic
profil
conclud
trisaccharid
requir
adjuv
activ
modif
aldehyd
hydroxyl
shown
echinocyst
acid
aryl
iodid
deriv
lack
aldehyd
retain
alcohol
function
fig
exhibit
potent
adjuv
activ
toxic
preclin
vaccin
model
use
fourcompon
vaccin
ova
test
dose
data
indic
aldehyd
previous
suggest
particip
schiff
base
format
presum
cell
surfac
receptor
target
marciani
requir
adjuv
activ
reveal
previous
unknown
role
alcohol
enhanc
activ
open
door
semisynthesi
easili
avail
altern
precursor
allow
detail
mechanist
studi
et
al
one
promis
approach
improv
effici
newli
develop
vaccin
given
combin
sever
adjuv
singl
formul
adjuv
system
et
al
develop
year
ago
liposomebas
adjuv
compris
two
immunostimul
mpl
liposom
synthet
nanospher
consist
phospholipid
bilay
encapsul
antigen
act
antigen
deliveri
vehicl
et
al
mpl
detoxifi
synthet
deriv
lipopolysaccharid
lp
bacteria
salmonella
minnesota
induc
activ
innat
immun
via
stimul
nfkb
transcript
activ
stimul
induct
agspecif
cell
produc
antibodi
q
saponaria
licens
gsk
antigen
inc
wholli
own
subsidiari
agenu
inc
lexington
usa
earli
evalu
adjuv
suggest
promot
high
agspecif
ab
respons
cell
respons
mice
high
agspecif
ab
respons
human
didierlaur
et
al
amphiphil
compound
known
hemolyt
properti
abrog
formul
liposom
presenc
cholesterol
beck
et
al
di
pasqual
result
accept
toler
profil
use
human
vaccin
contain
oilinwat
emuls
combin
mpl
cpg
oligodesoxynucleotid
agonist
liposom
complex
combin
adjuv
use
applic
cancer
immunotherapi
mechan
action
liposom
poorli
understood
despit
clinic
efficaci
therefor
studi
carri
order
tent
elucid
adjuv
effect
formul
observ
intramuscular
im
immun
mice
two
model
antigen
hepat
b
surfac
antigen
hbsag
ova
rapidli
accumul
resid
macrophag
dln
induc
activ
earli
event
organ
recruit
innat
immun
cell
activ
dc
subsequ
cell
prime
analysi
show
adjuv
effect
depend
integr
pathway
least
part
local
releas
highmobilitygroup
protein
detienn
et
al
recent
studi
report
directli
activ
human
monocytederiv
dendrit
cell
modc
promot
proinflammatori
transcript
program
model
endocytos
via
cholesteroldepend
mechan
accumul
lysosom
induc
destabil
pore
format
potenti
releas
content
result
inflammasom
activ
syk
tyrosin
kinas
cathepsinb
cystein
proteas
depend
cell
activ
cytokin
product
modc
lysosom
disrupt
could
also
affect
ag
process
transloc
cytosol
present
mhc
final
shown
cathepsin
b
contribut
adjuv
properti
agspecif
tcell
respons
vivo
adjuv
system
contain
combin
hbsag
shown
induc
strong
persist
humor
cellular
immun
respons
healthi
adult
b
induc
strongest
durabl
specif
cmi
two
dose
without
seriou
advers
event
respons
character
vitro
high
lymphoprolifer
high
moder
product
respons
confirm
ex
vivo
detect
produc
cell
vivo
measur
increas
level
serum
et
al
therefor
b
select
lead
develop
vaccin
experi
conduct
mous
model
recombin
varicellazost
viru
vzv
glycoprotein
e
ge
fluoresc
label
incorpor
hz
shingl
vaccin
formul
induc
rapid
transient
activ
innat
immun
system
inject
site
dln
lead
gener
high
number
effici
agload
dc
dln
promot
agspecif
adapt
immun
respons
didierlaur
et
al
compar
studi
immunogen
differ
formul
contain
subunit
ge
carri
vzvprime
mous
model
dendouga
et
al
model
chosen
order
mimic
clinic
set
larg
major
person
elev
risk
hz
vzv
seroposit
hz
candid
vaccin
compris
ge
b
mpl
shown
highli
immunogen
mice
induc
higher
respons
cell
express
andor
higher
humor
respons
compar
formul
differ
ag
dose
lower
dose
adjuv
mpl
correspond
e
f
respect
dendouga
et
al
furthermor
contribut
compon
b
induct
cellular
humor
respons
assess
immun
mice
ge
either
unadjuv
adjuv
mpl
liposom
result
show
gespecif
cytokin
produc
cell
respons
induc
geliposomempl
similar
low
magnitud
wherea
respons
induc
b
significantli
higher
fold
differ
geliposomempl
fold
differ
clearli
show
mpl
act
synergist
induc
high
frequenc
gespecif
cell
antig
antibodi
respons
addit
effect
rather
synergist
effect
observ
dendouga
et
al
didierlaur
et
al
result
suggest
b
vaccin
candid
appropri
clinic
assess
investig
molecular
cellular
mechan
adjuv
vaccin
undertaken
order
clarifi
immunostimul
function
combin
result
vivo
clinic
studi
show
combin
mpl
result
stimul
de
novo
pathway
trigger
individu
compon
mice
immun
twice
week
apart
rt
antigen
malaria
vaccin
formul
either
without
adjuv
mpl
includ
liposom
rt
recombin
protein
consist
repeat
sequenc
plasmodium
falciparum
circumsporozoit
protein
csprepeat
region
r
tcell
epitop
domain
link
hepat
b
surfac
antigen
hbsag
hbsag
alon
mori
et
al
cspspecif
immun
respons
measur
second
dose
result
clearli
show
mpl
act
synergist
induc
strong
antibodi
agspecif
cell
respons
contrast
low
level
cell
respons
gener
csp
investig
highlight
key
role
earli
releas
innat
resid
cell
nk
cell
ln
drain
inject
site
essenti
develop
cell
respons
immun
confirm
measur
level
cytokin
immun
mice
hb
adjuv
compon
induc
earli
product
peak
concentr
h
post
immun
pgml
wherea
mpl
alon
fail
significantli
induc
effect
result
synergi
control
macrophag
contain
adjuv
assess
human
clinic
trial
key
compon
recent
develop
malaria
hz
vaccin
candid
vaccin
develop
infecti
diseas
cancer
didierlaur
et
al
di
pasqual
recent
clinic
studi
prophylact
vaccin
malaria
hz
hiv
tuberculosi
efficaci
immunogen
safeti
point
view
tabl
therapeut
vaccin
melanoma
nsclc
alzheim
diseas
report
despit
effect
medicin
insecticidetr
net
indoor
insecticid
spray
malaria
kill
peopl
particularli
subsaharan
african
children
world
malaria
day
ag
candid
malaria
vaccin
rt
target
csp
express
plasmodium
sporozoit
preerythrocyt
stage
lifecycl
stage
mosquito
bite
liver
infect
rt
first
malaria
vaccin
candid
adjuv
system
use
et
al
howev
rt
shown
phase
ii
trial
well
toler
induc
strong
humor
cellular
immun
respons
improv
protect
plasmodium
falciparum
challeng
comparison
rt
kester
et
al
name
induc
high
level
anticsp
igg
titer
cspspecif
polyfunct
cell
express
associ
protect
experiment
malaria
challeng
model
adult
clinic
trial
children
adult
confirm
observ
seriou
advers
event
report
agnandji
et
al
olotu
et
al
ansong
et
al
white
et
al
levast
et
al
lerouxroel
et
al
therefor
develop
rt
stop
rt
ss
consequ
select
phase
iii
develop
analys
data
term
efficaci
immunogen
safeti
phase
iiii
trial
includ
adult
infant
children
subsaharan
countri
review
agnandji
et
al
clinic
trial
children
newli
adjuv
vaccin
led
conclus
clinic
safeti
except
unexplain
case
mening
one
phase
iii
adjuv
malaria
vaccin
trial
warrant
safeti
evalu
stassijn
et
al
import
insight
molecular
mechan
protect
immun
malaria
achiev
involv
addit
immunogen
analys
potenti
contribut
role
cspspecif
ab
cspspecif
cmi
protect
mori
et
al
kazmin
et
al
lead
identif
nfkb
pathway
van
den
berg
et
al
first
clinic
largescal
phase
iii
trial
rt
clinic
trial
partnership
evalu
malaria
vaccin
involv
infant
young
children
complet
decemb
site
african
countri
burkina
faso
gabon
ghana
kenya
malawi
mozambiqu
tanzania
safeti
efficaci
studi
rt
vaccin
show
prevent
mani
case
clinic
sever
malaria
month
dose
vaccin
efficaci
higher
children
month
infant
week
even
modest
level
final
result
rt
clinic
trial
partnership
trial
show
enhanc
efficaci
administr
booster
dose
age
categori
month
first
three
inject
regard
risk
safeti
mosquirix
similar
vaccin
common
side
effect
fever
pain
swell
inject
site
thu
vaccin
potenti
make
substanti
contribut
malaria
control
use
combin
effect
control
measur
especi
area
high
transmiss
ratio
benefitrisk
mosquirix
found
accept
european
medicin
agenc
committe
medicin
product
human
use
emachmp
deliv
posit
scientif
opinion
use
outsid
european
union
eu
ema
press
releas
furthermor
world
health
organ
recommend
largescal
pilot
implement
vaccin
young
children
fourdos
schedul
african
region
moder
high
parasit
transmiss
three
countri
ghana
kenya
malawi
select
largescal
pilot
program
start
first
malaria
tabl
clinic
trial
involv
newli
adjuv
prophylact
vacccin
vaccin
provid
young
children
routin
immun
programm
malaria
vaccin
implement
programm
result
two
phase
provid
insight
feasibl
deliv
vaccin
reallif
set
safeti
profil
context
routin
use
contribut
futur
decis
widerscal
use
vaccin
herp
zoster
hz
also
known
shingl
common
pain
diseas
occur
princip
adult
age
year
immunocompromis
individu
hz
caus
reactiv
latent
varicellazost
viru
vzv
dorsal
root
cranial
ganglia
usual
mani
year
primari
vzv
infect
chickenpox
occur
childhood
hz
lead
seriou
complic
includ
post
herpet
neuralgia
phn
phase
iii
trial
show
subunit
vaccin
contain
recombin
vzv
glycoprotein
e
ge
ag
b
call
hzsu
well
toler
highli
immunogen
cell
humor
immun
respons
immunogen
live
attenu
vaccin
lerouxroel
et
al
phase
ii
trial
adult
year
age
evalu
differ
formul
contain
ge
combin
differ
schedul
show
formul
elicit
robust
humor
cell
immun
respons
persist
least
year
vaccin
two
dose
ge
b
immunogen
one
chlibek
et
al
followup
studi
conduct
healthi
adult
shown
ge
specif
cell
antig
antibodi
respons
persist
year
two
dose
b
without
safeti
concern
therefor
dose
ge
select
clinic
develop
two
random
placebocontrol
phase
iii
efficaci
trial
countri
evalu
efficaci
safeti
hzsu
compar
placebo
older
adult
year
age
particip
receiv
two
im
dose
vaccin
placebo
month
apart
hzsu
demonstr
high
efficaci
adult
year
year
respect
prevent
hz
phn
age
group
accept
safeti
profil
lal
et
al
cunningham
et
al
robust
immun
respons
remain
year
vaccin
assess
subset
particip
phase
iii
trial
persist
antig
ab
gespecif
polyfunct
cell
respons
like
import
mechan
hzsu
confer
high
efficaci
hz
cunningham
et
al
extens
studi
origin
phase
ii
trial
report
chlibek
et
al
chlibek
et
al
observ
hz
su
induc
cell
mediat
humor
immun
persist
year
post
initi
vaccin
adult
year
old
confirm
statist
predict
model
base
immun
respons
measur
earlier
time
point
immun
respons
predict
persist
year
initi
vaccin
schwarz
et
al
accept
benefit
risk
profil
led
licens
us
food
drug
administr
fda
hzsu
vaccin
market
author
valid
throughout
eu
march
shingrix
innherp
zoster
vaccin
shingrix
prefer
zostavax
live
attenu
vaccin
provid
strong
protect
shingl
phn
first
introduc
bacillu
bcg
vaccin
current
licens
vaccin
avail
protect
tuberculosi
tb
diseas
caus
bacteria
mycobacterium
tuberculosi
mtb
protect
children
mening
sever
form
dissemin
tb
death
offer
limit
protect
pulmonari
tb
adolesc
adult
form
diseas
respons
vast
major
transmiss
tbrelat
morbid
mortal
therefor
urgent
need
new
improv
vaccin
tb
control
diseas
continu
pose
global
health
threat
million
death
van
der
meeren
et
al
candid
vaccin
contain
recombin
fusion
protein
deriv
two
immunogen
tuberculosi
ag
first
phase
iii
random
control
clinic
studi
carri
belgium
healthi
adult
volunt
result
show
vaccin
clinic
well
toler
induc
high
persist
three
year
specif
tcell
coexpress
ab
respons
support
clinic
evalu
tbendem
set
lerouxroel
et
al
similar
conclus
drawn
phase
ii
control
trial
conduct
healthi
hiv
uninfect
adolesc
live
area
high
tb
burden
south
africa
pennnicholson
et
al
phase
ii
studi
given
infant
concomitantli
expandedprogrammeonimmun
epi
vaccin
accept
safeti
profil
result
suggest
interfer
immunogen
profil
occur
follow
coadministr
epi
vaccin
two
dose
elicit
higher
immun
respons
one
dose
ikodo
et
al
larg
phase
iib
trial
conduct
hivuninfect
adult
latent
infect
mtb
three
african
countri
e
shown
provid
protect
mtbinfect
adult
activ
pulmonari
tb
without
evid
safeti
concern
van
der
meeren
et
al
result
suggest
evalu
possibl
vaccin
strategi
tb
approxim
million
peopl
live
hiv
end
million
peopl
becom
newli
infect
hivaid
key
fact
juli
treatment
avail
treat
prevent
hiv
infect
vaccin
current
licens
despit
ongo
prevent
effort
urgent
need
safe
effect
prophylact
vaccin
prevent
infect
induct
neutral
ab
induct
strong
cellular
immun
respons
order
delay
progress
reduc
transmiss
rate
high
risk
popul
major
aim
hiv
vaccin
although
clinic
attempt
disappoint
contribut
valuabl
insight
immun
protect
immun
random
doubleblind
studi
conduct
healthi
hivseroneg
adult
show
vaccin
formul
contain
gp
nef
tat
ag
b
induc
strong
ab
respons
cell
respons
character
high
lymphoprolif
capac
product
maintain
month
last
vaccin
dose
cell
respons
observ
lerouxroel
et
al
studi
conduct
differ
adjuv
underlin
superior
respons
b
comparison
adjuv
confirm
previou
find
anoth
candid
vaccin
consist
recombin
fusion
protein
encod
four
clade
b
ag
revers
transcriptas
rt
nef
adjuv
studi
phase
iii
trial
healthi
hivseroneg
volunt
van
braeckel
et
al
vaccin
shown
immunogen
accept
safeti
profil
two
dose
strong
polyfunct
phenotyp
persist
cell
respons
induc
suggest
vaccin
merit
evalu
prophylact
set
potenti
diseasemodifi
therapeut
vaccin
subject
phase
clinic
studi
subject
initi
harrer
et
al
phase
ii
studi
conduct
b
candid
vaccin
healthi
adult
order
evalu
effect
chloroquin
specif
cell
respons
safeti
profil
booster
dose
lerouxroel
et
al
result
show
booster
dose
administ
alon
two
day
chloroquin
induc
strong
ab
immun
respons
robust
specif
cell
respons
signific
cell
respons
suggest
two
primari
dose
b
vaccin
induc
longlast
memori
b
cell
cell
respons
healthi
adult
confirm
previou
find
phase
iii
studi
lerouxroel
et
al
vaccin
shown
immunogen
clinic
accept
safeti
profil
nt
show
signific
viral
efficaci
antiretrovir
adult
result
confirm
long
term
studi
ding
et
al
harrer
et
al
use
immunotherapeut
vaccin
cancer
patient
aim
induc
immun
respons
exist
tumor
rather
protect
healthi
individu
use
phase
ii
iii
trial
melanoma
lung
cancer
surgic
resect
disappoint
result
recent
studi
shortli
present
enhanc
product
gangliosid
observ
differ
human
tumor
type
includ
melanoma
vaccin
conjug
carrier
keyhol
limpet
hemocyanin
klh
administ
induc
high
igm
igg
ab
respons
fail
show
benefici
effect
melanoma
patient
shown
phase
iii
clinic
trial
term
relaps
free
surviv
distant
metastasisfre
surviv
overal
surviv
eggermont
et
al
fiveyear
surviv
occur
less
patient
complet
resect
nonsmallcelllung
cancer
nsclc
therapeut
cancer
vaccin
potenti
elimin
remain
cancer
cell
complet
resect
therebi
decreas
relaps
rate
improv
surviv
vansteenkist
et
al
agspecif
immunotherapi
enhanc
tcell
respons
specif
express
tumor
ag
context
use
melanoma
antigen
famili
ag
express
wide
array
malign
applic
cancer
immunotherapi
esfandiari
ghafourifard
immunotheraput
vaccin
assess
clinic
efficaci
intern
multicent
phase
iii
studi
surgic
resect
nsclc
studi
confirm
accept
clinic
safeti
profil
vaccin
improv
overal
surviv
therefor
develop
use
nslc
stop
vansteenkist
et
al
similar
conclus
drawn
phase
iii
trial
vaccin
patient
resect
stage
iii
melanoma
led
arrest
clinic
develop
vaccin
use
melanoma
dreno
et
al
pathogenesi
alzheim
diseas
ad
associ
accumul
amyloid
andor
hyperphosphoryl
tau
protein
brain
activ
immunotherapi
ad
extens
studi
approach
order
evalu
abil
elicit
antibodi
induc
clearanc
reduc
accumul
brain
vaccin
full
length
peptid
success
elicit
human
subject
ad
advers
effect
meningoenceph
observ
attribut
cell
activ
winblad
et
al
avoid
safeti
issu
ntermin
peptid
conjug
carrier
protein
call
vanutid
cridificar
produc
preclin
studi
shown
gener
ntermin
ab
adult
nonhuman
primat
without
induc
cell
respons
support
clinic
studi
sever
phase
ii
trial
patient
mild
moder
ad
conduct
usa
europ
japan
use
dose
without
adjuv
placebo
investig
doserang
safeti
immunogen
long
term
treatment
arai
et
al
pasquier
et
al
elicit
high
sustain
igg
ab
titer
compar
alon
highlight
role
effect
differ
observ
among
three
dose
test
furthermor
dose
level
without
gener
safe
well
toler
exploratori
cognit
evalu
show
differ
treatment
group
placebo
similar
safeti
toler
immunogen
profil
observ
long
term
phase
ii
extens
studi
suggest
side
effect
limit
principl
antiamyloid
activ
immunotherapi
et
al
howev
larger
trial
adequ
durat
optim
dose
may
need
attest
efficaci
vaccin
therapi
ad
overview
provid
summari
recent
report
mechan
action
promis
triterpen
glycosid
vaccin
adjuv
isol
quillaja
saponaria
relev
clinic
applic
compound
show
potent
adjuv
activ
stimul
humor
cellmedi
immun
wide
varieti
ag
present
advantag
aluminium
salt
induc
immun
respons
necessari
control
intracellular
pathogen
unlik
singl
mechan
action
could
explain
effect
adjuv
contribut
highlight
role
act
apc
cell
interact
aldehyd
function
tcell
receptor
deliv
costimulatori
signal
togeth
present
ag
peptid
apc
tcell
result
activ
lymphocyt
secret
cytokin
import
immun
effector
mechan
elimin
infect
cell
novel
mechan
action
base
activ
caspas
inflammasom
mous
apc
lead
secret
proinflammatori
cytokin
import
respons
synthesi
nearli
structur
analog
detail
sar
studi
lead
easili
avail
stabl
molecul
improv
activitytox
profil
among
novel
aryl
iodin
simplifi
echinocyst
deriv
show
potent
adjuv
activ
consider
attenu
toxic
signal
pathway
formul
liposom
rapid
accumul
dln
resid
macrophag
induc
activ
releas
event
orchestr
recruit
innat
immun
cell
activ
dc
lead
cell
prime
direct
activ
dc
also
report
result
releas
cathepsin
b
contribut
specif
cell
respons
vivo
develop
adjuv
system
includ
combin
immunostimul
formul
mpl
liposom
shown
act
synergist
enhanc
cmi
respons
high
number
clinic
applic
term
immunogen
efficaci
safeti
alon
adjuv
system
mani
prophylact
vaccin
complex
pathogen
eg
malaria
herp
zoster
tuberculosi
hiv
therapeut
vaccin
eg
cancer
ad
licens
us
fda
vaccin
shingl
call
hzsu
contain
commerci
eu
sinc
march
first
malaria
vaccin
contain
rt
receiv
regulatori
approv
ema
use
outsid
europ
current
explor
subsaharan
region
use
routin
disappoint
phase
iii
clinic
result
term
diseasefre
surviv
patient
immunotherapeut
vaccin
adjuv
nsclc
melanoma
despit
promis
result
phase
ii
trial
encourag
result
phase
ii
trial
confirm
long
term
treatment
immunotherapeut
vaccin
vanutid
cridificar
adjuv
alzheim
diseas
well
toler
accept
safeti
profil
develop
adjuv
vaccin
repres
area
constant
evolut
substanti
advanc
past
two
decad
ass
key
compon
multipl
vaccin
target
infect
endem
diseas
develop
countri
recent
research
led
commerci
approv
two
vaccin
hz
adult
malaria
children
respect
contain
part
formul
ensur
continu
suppli
excit
molecul
research
aim
near
futur
find
altern
innov
process
produc
compound
larg
scale
base
plant
cellcultur
might
overcom
limit
current
tradit
techniqu
extract
tediou
purif
process
chemic
synthesi
involv
mani
complex
reaction
howev
synthet
technolog
initi
use
first
synthesi
subsequ
appli
prepar
novel
structur
analog
potent
activ
low
toxic
lead
sar
studi
better
understand
mode
action
work
area
could
facilit
novel
saponin
design
lead
discoveri
new
adjuv
improv
adjuvantantigen
combin
futur
vaccin
particularli
infecti
tropic
diseas
dengu
leishmaniasi
chaga
diseas
continu
caus
signific
morbid
mortal
develop
countri
